Advertisement

Particular Antiepileptic Drugs and Foetal Malformations

  • MJ Eadie
  • FJE Vajda

Abstract

This chapter attempts to discuss the published information concerning the risks of structural malformations occurring in foetuses exposed to those individual antiepileptic drugs that have been widely enough used in women with epilepsy for relevant data to be available. There appears to be persuasive evidence that valproate is a dose-related teratogen, with certain malformations such as neural tube defects seeming to be particularly associated with high maternal dosage of the drug. Evidence also points towards topiramate being a dose-related teratogen. On the basis of the available data the possibility that the remaining currently used drugs are teratogens cannot be excluded, but there appears to be enough evidence to indicate that any teratogenic hazard arising from exposure to them is quite small.

Keywords

Antiepileptic Drug Foetal Malformation Malformation Rate Intrauterine Exposure Lamotrigine Monotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Akar M, Dilli D, Yilmaz Y, Erdeve O, Oyuz S, Uras N, Dilmen U (2012) A case of fetal carbamazepine syndrome with right hemihypoplasia of the entire body. Genet Couns 23:19–24PubMedGoogle Scholar
  2. Andermann E, Dansky L, Andermann F, Loughnan PM, Gibbons J (1982) Minor congenital malformations and dermatoglyphic alterations in the offspring of epileptic women: a clinical investigation of the teratogenic effect of anticonvulsant medication. In: Janz D, Bossi L, Dam M, Helge H, Richens A, Schmidt D (eds) Epilepsy, pregnancy and the child. Raven, New York, pp 235–249Google Scholar
  3. Arpino C, Bresarini S, Robert W et al (2000) Teratogenic effects of antiepileptic drugs: use of an international database on malformation and drug exposure (MADRE). Epilepsia 41:1436–1443CrossRefPubMedGoogle Scholar
  4. Artama M, Auvinen A, Raudaskoski T, Isojarvi I, Isojarvi J (2005) Antiepileptic drug use of women with epilepsy and congenital malformations in the offspring. Neurology 64:1874–1878CrossRefPubMedGoogle Scholar
  5. Bailey CJ, Pool RW, Poskitt EME, Harris F (1983) Valproic abnormality and fetal abnormality. Br Med J 286:190CrossRefGoogle Scholar
  6. Barr MJ, Pozanski AK, Schmickel RD (1974) Digital hypoplasia and anticonvulsants during gestation; a teratogenic syndrome? J Pediatr 84:254–257CrossRefPubMedGoogle Scholar
  7. Bjerkedal T, Czeizel A, Goujard J et al (1982) Valproic acid and spina bifida. Lancet 2:1096CrossRefPubMedGoogle Scholar
  8. Bonnot O, Vollset SE, Godet PF, d’Amato T, Dalery J, Robert E (2003) In utero exposure to benzodiazepine: is there a risk for anal atresia with lorazepam? Encéphale 29:553–559PubMedGoogle Scholar
  9. Bromfield EB, Dworetzky BA, Wyszynski DF, Smith CR, Baldwin EJ, Holmes LB (2008) Valproate teratogenicity and epilepsy syndromes. Epilepsia 49:2122–2124CrossRefPubMedGoogle Scholar
  10. Campbell E, Kennedy F, Russell A et al (2014) Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry 85:1029–1034CrossRefPubMedGoogle Scholar
  11. Canger R, Battino D, Canevini MP et al (1999) Malformations in offspring of women with epilepsy: a prospective study. Epilepsia 40:1231–1236CrossRefPubMedGoogle Scholar
  12. Chaudhry SA, Jong G, Koren G (2014) The fetal safety of levetiracetam. Reprod Toxicol 46C:40–45CrossRefGoogle Scholar
  13. Cunnington M, Ferber S, Quartey G, International Lamotrigine Pregnancy Registry Scientific Advisory Committee (2007) Effect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study. Epilepsia 48:1207–1210CrossRefPubMedGoogle Scholar
  14. Curran MAW (1987) The management of epilepsy in women of child-bearing age and the Australian experience of valproate in pregnancy. Clin Exp Neurol 23:145–148PubMedGoogle Scholar
  15. Danks DM, Barry JE, Sheffield LJ (1974) Digital hypoplasia and anticonvulsants during pregnancy. J Pediatr 85:877CrossRefPubMedGoogle Scholar
  16. Di Liberti JH, Farndon RA, Dennis NR, Curry CJR (1984) The fetal valproate syndrome. Am J Med Genet 19:473–481CrossRefGoogle Scholar
  17. Diav-Citrin O, Shectman S, Arnon J, Ornoy A (2001) Is carbamazepine teratogenic? A prospective controlled study of 210 pregnancies. Neurology 57:321–324CrossRefPubMedGoogle Scholar
  18. Diav-Cirtin O, Shechhman S, Bar-Oz, Cantrell D, Amon J, Ornoy A (2008) Pregtnancy outcome after in utero exposure to valproate - evidence of dose relationship in teratogenic effect. CNS Drugs 22: 325–335Google Scholar
  19. Dolovich LR, Addis A, Vaillancourt JM, Power JD, Koren G, Einarson TR (1998) Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case–control studies. Br Med J 317:839–843CrossRefGoogle Scholar
  20. Dravet C, Julian C, Legras C et al (1992) Epilepsy, antiepileptic drugs, and malformations in children of women with epilepsy: a French prospective cohort study. Neurology 42(Suppl 5):75–82PubMedGoogle Scholar
  21. Eadie MJ (2008) Antiepileptic drugs as human teratogens. Expert Opin Drug Saf 7:195–201CrossRefPubMedGoogle Scholar
  22. Enato E, Moretti M, Koren G (2011) The fetal safety of benzodiazepines: an updated meta-analysis. J Obstet Gynaecol Can 33:46–48PubMedGoogle Scholar
  23. Fujii H, Goel A, Bernard N et al (2013) Pregnancy outcomes following gabapentin use. Results of a prospective comparative study. Neurology 80:1565–1570PubMedCentralCrossRefPubMedGoogle Scholar
  24. Hanson JW, Smith DW (1975) The fetal hydantoin syndrome. J Pediatr 87:285–290CrossRefPubMedGoogle Scholar
  25. Hernandez-Diaz S, Smith CR, Wyzszynski D (2007) Risk of major malformations among infants exposed to carbamazepine during pregnancy. Proc 47th Teratol Soc Meet Birth Defects Res (Part A) 79:357 (Cited by Wlodarczyl 2012, loc cit)Google Scholar
  26. Hernandez-Diaz S, Smith CR, Shen A et al (2012) Comparative study of antiepileptic drugs during pregnancy. Neurology 78:1692–1699CrossRefPubMedGoogle Scholar
  27. Hill RM, Verniaud WM, Horning MD, McCulley LB, Morgan NF (1974) Infants exposed in utero to antiepileptic drugs. Am J Dis Child 127:645–653CrossRefPubMedGoogle Scholar
  28. Holmes LB, Hernandez-Diaz S (2012) Newer anticonvulsants: lamotrigine, topiramate and gabapentin. Birth Defects Res (Part A) 94:599–606CrossRefGoogle Scholar
  29. Holmes LB, Wyszynski DF, Lieberman E, for the AED Pregnancy Registry (2004) The AED (antiepileptic drug) pregnancy registry. A 6-year experience. Arch Neurol 61:673–678CrossRefPubMedGoogle Scholar
  30. Holmes LB, Baldwin EJ, Smith CR, Habecker E, Glassman L, Wong SL, Wyuszynski DF (2008) Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 70:2152–2158CrossRefPubMedGoogle Scholar
  31. Holmes LB, Mittendorf R, Shen A, Smith CR, Hernandez-Diaz S (2011) Fetal effects of anticonvulsant polytherapies. Arch Neurol 68:1275–1281CrossRefPubMedGoogle Scholar
  32. Hunt S, Russell A, Smithson WH et al (2008) Topiramate in pregnancy. Preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 71:272–276CrossRefPubMedGoogle Scholar
  33. Jacobsen PE, Henriksen TB, Haubek D, Østergaard JR (2014) Prenatal exposure to antiepileptic drugs and dental agenesis. PLoS One 9, e84420PubMedCentralCrossRefPubMedGoogle Scholar
  34. Jager-Roman E, Deichl A, Jakob S (1986) Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. J Pediatr 108:997–1004CrossRefPubMedGoogle Scholar
  35. Janz D, Fuchs U (1964) Are anti-epileptic drugs harmful when given during pregnancy? Ger Med Mont 9:20–22Google Scholar
  36. Jentink J, Dolk H, Loane MA, Wellesley D, Game E, de Jong-van den Berg L, EUROCAT Antiepileptic Study Group (2010) Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case–control study. Br Med J 341:c6581CrossRefGoogle Scholar
  37. Jones KL, Lacro RV, Johnson KA, Adams J (1989) Pattern of malformations in children of women treated with carbamazepine during pregnancy. N Engl J Med 320:1661–1666CrossRefPubMedGoogle Scholar
  38. Kaaja E, Kaaja R, Hiilesmaa V (2003) Major malformations in offspring of women with epilepsy. Neurology 60:575–579CrossRefPubMedGoogle Scholar
  39. Kallen AJ (1994) Maternal carbamazepine and infant spina bifida. Reprod Toxicol 8:203–205CrossRefPubMedGoogle Scholar
  40. Kallen B, Robert E, Mastroiacovo P, Martinez-Frias ML, Castilla EE, Cocchi G (1989) Anticonvulsant drugs and malformations is there a drug specificity? Eur J Epidemiol 5:31–36CrossRefPubMedGoogle Scholar
  41. Kaneko S, Battino D, Andermann E et al (1999) Congenital malformations due to antiepileptic drugs. Epilepsy Res 33:145–158CrossRefPubMedGoogle Scholar
  42. Kini U, Adab N, Vinten J, Fryer A, Clayton-Smith J, Liverpool and Manchester Neurodevelopmental Study Group (2006) Dysmorphic features: an important clue to the diagnosis and severity of fetal anticonvulsant syndromes. Arch Dis Child Neonatal Ed 91:F90–F95CrossRefGoogle Scholar
  43. Kjaer D, Horvath-Puhó E, Christensen J, Vestergaard M, Czeizel AE, Sørensen HT, Olsen J (2007) Use of phenytoin, phenobarbital, or diazepam during pregnancy and the risk of congenital abnormalities: a case-time-control study. Pharmacoepidemiol Drug Saf 16:181–188CrossRefPubMedGoogle Scholar
  44. Koch S, Losche G, Jager-Romän C, Jakob S, Rating D, Deichl A, Helge H (1992) Major and minor birth malformations and antiepileptic drugs. Neurology 42(4 Suppl 5):83–88PubMedGoogle Scholar
  45. Kondo T, Kaneko S, Amano Y, Egawa I (1996) Preliminary report of teratogenic effect of zonisamide in the offspring of treated women with epilepsy. Epilepsia 37:1242–1244CrossRefPubMedGoogle Scholar
  46. Kozma C (2001) Valproic acid embryopathy: report of two siblings with further expansion of the phenotypic abnormalities and a review of the literature. Am J Med Genet (Part A) 98:168–175CrossRefGoogle Scholar
  47. Lin AE, Peller AJ, Westgate M-N, Houda K, Franz A, Holmes LB (2004) Clonazepam use in pregnancy and the risk of malformation. Birth Defects Res (Part A) 70:534–536CrossRefGoogle Scholar
  48. Lindhout D, Meinardi H (1984) Spina bifida and in utero exposure to valproate. Lancet 2:396CrossRefPubMedGoogle Scholar
  49. Lindhout D, Omtzigt JG (1992) Pregnancy and the risk of teratogenicity. Epilepsia 33(Suppl 4):S41–S48CrossRefPubMedGoogle Scholar
  50. Lindhout D, Schmidt D (1986) In-utero exposure to valproate and neural-tube defects. Lancet 2:1392–1393CrossRefGoogle Scholar
  51. Little BB, Santos-Ramos R, Newell JF, Mayberry MC (1993) Megadose carbamazepine during the period of neural tube closure. Obstet Gynecol 82:705–708PubMedGoogle Scholar
  52. Loughnan PM, Gold H, Vance JC (1973) Phenytoin teratogenicity in man. Lancet 1:70–72CrossRefPubMedGoogle Scholar
  53. Lype M, Henry P, Aravind C, Arun K (2008) Baller-Gerold syndrome: further evidence for association with prenatal exposure to valproate. Ann Indian Acad Neurol 11:52–55PubMedCentralCrossRefPubMedGoogle Scholar
  54. Mahwinney E, Craig J, Morrow J et al (2013) Levetiracetam in pregnancy. Results from the UK and Ireland epilepsy and pregnancy registers. Neurology 80:401–405Google Scholar
  55. Marguilis AV, Mitchell AA, Gilboa SM et al (2012) Use of topiramate in pregnancy and risk of oral clefts. Am J Obstet Gynecol 207:405 e1–e7Google Scholar
  56. Matalon S, Schectman S, Goldzweig G, Ornoy A (2002) The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures. Reprod Toxicol 16:9–17CrossRefPubMedGoogle Scholar
  57. Mawer G, Briggs M, Baker GA et al (2010) Pregnancy with epilepsy: obstetric and neonatal outcome of a controlled study. Seizure 19:112–119PubMedCentralCrossRefPubMedGoogle Scholar
  58. McElhatton PR (1994) The effect of benzodiazepine use during pregnancy and lactation. Reprod Toxicol 8:461–475CrossRefPubMedGoogle Scholar
  59. McMahon CL, Braddock SR (2001) Septo-optic dysplasia as a manifestation of valproic acid embryopathy. Teratology 64:83–86CrossRefPubMedGoogle Scholar
  60. Meador KJ, Baker JA, Finnell RH et al (2006) In utero fetal drug exposure. Fetal death and malformations. Neurology 67:407–412PubMedCentralCrossRefPubMedGoogle Scholar
  61. Meador K, Reynolds MW, Crean S, Fahrbach K, Probst C (2008) Pregnancy outcomes in women with epilepsy: a systematic review and analysis of published pregnancy registers and cohorts. Epilepsy Res 81:1–13PubMedCentralCrossRefPubMedGoogle Scholar
  62. Meischenguiser R, D’Giano CH, Ferraro SM (2004) Oxcarbazepine in pregnancy: clinical experience in Argentina. Epilepsy Behav 5:163–167CrossRefPubMedGoogle Scholar
  63. Miki T, Reo T, Tohru K, Joseph B, Gideon K, Elizabeth U, Shinya I (2014) Risks of congenital malformations in offspring exposed to valproic acid in utero: Emergence of the signals over the last 30 years. J Popul Ther Clin Pharmacol 21:2 (e277)Google Scholar
  64. Mines D, Tennis P, Curkendall SM et al (2014) Topiramate use in pregnancy and the birth prevalence of oral clefts. Pharmacoepidemiol Drug Saf 23:1017–1025CrossRefPubMedGoogle Scholar
  65. Molgaard-Nielsen D, Hviid A (2011) Newer-generation antiepileptic drugs and the risk of major birth defects. J Am Med Assoc 305:1996–2002CrossRefGoogle Scholar
  66. Monson RR, Rosenberg L, Hartz SC, Shapiro S, Heinonen OP, Stone D (1973) Diphenylhydantoin and selected congenital malformations. N Engl J Med 289:1049–1052CrossRefPubMedGoogle Scholar
  67. Montouris G (2003) Gabapentin exposure in human pregnancy: results from the Gabapentin Pregnancy Registry. Epilepsy Behav 4:310–317CrossRefPubMedGoogle Scholar
  68. Montouris G (2005) Safety of the newer antiepileptic drug oxcarbazepine during pregnancy. Curr Med Res Opin 21:693–701CrossRefPubMedGoogle Scholar
  69. Moore SJ, Turpenny P, Quinn A, Glover S, Lloyd DJ, Montgomery T, Dean JC (2000) A clinical study of 57 children with fetal anticonvulsant syndromes. J Med Genet 37:489–497PubMedCentralCrossRefPubMedGoogle Scholar
  70. Morrow J, Russell A, Guthrie E et al (2006) Malformation risk of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 77:193–198PubMedCentralCrossRefPubMedGoogle Scholar
  71. Nelson MM, Forfar IO (1971) Association between drugs administered during pregnancy and congenital abnormalities in the fetus. Br Med J 1:523–527PubMedCentralCrossRefPubMedGoogle Scholar
  72. Omtzigt JG, Los FJ, Grobbee DE et al (1992) The risk of spina bifida aperta after first trimester exposure to valproate in a prenatal cohort. Neurology 42(Suppl 5):119–125PubMedGoogle Scholar
  73. Ornoy A, Cohen E (1996) Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Arch Dis Child 75:517–520PubMedCentralCrossRefPubMedGoogle Scholar
  74. Ornoy A, Zvi N, Arnon J, Waajnberg R, Schectman S, Diav-Citrin O (2008) The outcome of pregnancy following topiramate treatment: a study of 52 pregnancies. Reprod Toxicol 25:388–389CrossRefPubMedGoogle Scholar
  75. Phelan MC, Pellock JM, Nance WE (1982) Discordant expression of the fetal hydantoin syndrome in heteropaternal dizygotic twins. N Engl J Med 307:99–101CrossRefPubMedGoogle Scholar
  76. Robert E, Guibaud P (1982) Maternal valproic acid and congenital neural tube defects. Lancet 2:937CrossRefPubMedGoogle Scholar
  77. Robert E, Rosa F (1983) Valproate and birth defects. Lancet 2:1142CrossRefPubMedGoogle Scholar
  78. Rosenberg L, Mitchall AA, Parsells JL, Pashayan H, Louik C, Shapiro S (1983) Lack of relation of oral clefts to diazepam use during pregnancy. N Engl J Med 309:1282–1285CrossRefPubMedGoogle Scholar
  79. Sabers A, Dam M, a-Rogvi-Hansen B et al (2004) Epilepsy and pregnancy: lamotrigine as main drug used. Acta Neurol Scand 109:9–13CrossRefPubMedGoogle Scholar
  80. Safra MJ, Oakey GPJ (1975) Association between cleft lip with or without cleft palate and prenatal exposure to diazepam. Lancet 2:478–480CrossRefPubMedGoogle Scholar
  81. Samrén EB, van Duijn CM, Koch S et al (1997) Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 38:981–990CrossRefPubMedGoogle Scholar
  82. Samrén EB, van Duijn CM, Lieve Christiaens GCM, Hofman A, Lindhout D (1999) Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 46:739–746CrossRefPubMedGoogle Scholar
  83. Shapiro S, Hartz SC, Siskind V et al (1976) Anticonvulsants and parental epilepsy in the development of birth defects. Lancet 1:272–275CrossRefPubMedGoogle Scholar
  84. Speidel BD, Meadow SR (1972) Maternal epilepsy and abnormalities of the fetus and newborn. Lancet 2:839–843CrossRefPubMedGoogle Scholar
  85. Staples RE (1972) Teratology. In: Penry JK, Schmidt RP, Woodbury DM (eds) Antiepileptic drugs. Raven, New York, pp 55–62Google Scholar
  86. Starreveld-Zimmerman AAE, Van Der Kolk WJ, Meinardi H, Elshove J (1973) Are anticonvulsants teratogenic? Lancet 2:48–49CrossRefPubMedGoogle Scholar
  87. Tomson T, Battino D, Bonizzoni E et al (2011) Dose-dependent risk of malformation with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 10:609–617CrossRefPubMedGoogle Scholar
  88. Vajda FJE, Eadie MJ (2005) Maternal valproate dosage and foetal malformations. Acta Neurol Scand 112:137–143CrossRefPubMedGoogle Scholar
  89. Vajda FJ, O’Brien TJ, Hitchcock A, Graham J, Cook M, Lander C, Eadie MJ (2004) Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. J Clin Neurosci 11:854–858CrossRefPubMedGoogle Scholar
  90. Vajda F, Hitchcock A, Graham J, Solinas C, O’Brien TJ, Lander CM, Eadie MJ (2006) Foetal malformations and seizure control: 52 months data of the Register, Australian Pregnancy. Eur J Neurol 13:645–654CrossRefPubMedGoogle Scholar
  91. Vajda FJE, Graham J, Hitchock AA, O’Brien TJ, Lander CM, Eadie MJ (2010) Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure 19:555–561CrossRefGoogle Scholar
  92. Vajda FJE, O’Brien TJ, Graham J, Lander CM, Eadie MJ (2013a) Associations between particular types of fetal malformation and antiepileptic drug exposure. Acta Neurol Scand 128:228–234CrossRefPubMedGoogle Scholar
  93. Vajda FJE, O’Brien TJ, Graham J, Lander CM, Eadie MJ (2013b) Dose-dependency of fetal malformations associated with valproate. Neurology 81:999–1003CrossRefPubMedGoogle Scholar
  94. Vajda FJE, O’Brien TJ, Lander CM, Graham J, Eadie MJ (2014) The teratogenicity of the newer antiepileptic drugs – an update. Ácta Neurol Scand 130: 234–238Google Scholar
  95. Veiby G, Daltveit AK, Engelsen BA, Gilhus NE (2014) Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J Neurol 261:579–588CrossRefPubMedGoogle Scholar
  96. Wheatley D (1963) Drugs in pregnancy survey. Practitioner 191:775–780Google Scholar
  97. Wlodarczyk BJ, Palacios AM, George TM, Finnell TH (2012) Antiepileptic drugs and pregnancy outcomes. Am J Med Genet A 158A:2071–2090PubMedCentralCrossRefPubMedGoogle Scholar
  98. Wyszynski DF, Nambisan M, Surve T, Alsdorf RM, Smith CR, Holmes LB, Antiepileptic Drug Pregnancy Registry (2005) Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 64:961–965CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • MJ Eadie
    • 1
  • FJE Vajda
    • 2
  1. 1.Clinical Neurology and NeuropharmacologyUniversity of Queensland, and Honorary Consultant Neurologist, Royal Brisbane and Women’s HospitalBrisbaneAustralia
  2. 2.Department of Medicine and Neurology Director of the Australian Epilepsy and Pregnancy RegisterUniversity of Melbourne and Royal Melbourne HospitalMelbourneAustralia

Personalised recommendations